Quick Summary
- On April 16, 2026, HIMS shares rallied approximately 13% driven by FDA announcements regarding peptide regulatory evaluations
- Advisory committee sessions scheduled for July 23-24 will assess multiple peptides for potential 503A Bulks List inclusion
- BofA Securities increased its price objective to $25 from $21 while retaining its Neutral stance
- Analysts characterize this as a long-term tailwind with limited immediate earnings impact
- Company insiders have divested roughly $3.4 million in shares over the last quarter without any buying activity
Shares of Hims & Hers Health (HIMS) experienced a sharp rally of up to 13.72% on April 16, 2026, triggered by the FDA’s announcement that it would convene advisory committee sessions to examine various wellness peptides presently subject to regulatory restrictions.
Hims & Hers Health, Inc., HIMS
The regulatory agency published documentation outlining Pharmacy Compounding Advisory Committee sessions slated for July 23 and 24. These gatherings will center on evaluating multiple peptide-based bulk drug substances for potential addition to the 503A Bulks List. This represents a preliminary procedural action rather than regulatory clearance.
Public statements from RFK Jr. regarding prospective FDA policy modifications further amplified investor optimism. The agency is considering removing limitations on as many as 12 peptides, with evaluation processes extending through February 2027.
The equity had already demonstrated momentum. During the preceding seven days, HIMS climbed approximately 25%, based on InvestingPro statistics.
Bank of America Increases Valuation Target
BofA Securities adjusted its price objective on HIMS upward to $25 from $21, maintaining its Neutral assessment. The investment bank elevated its target valuation multiple to roughly 25.5 times from 21.5 times, referencing expanded peer multiples and peptide-related possibilities.
BofA observed the development might enable the organization to redirect current GLP-1 compounding infrastructure toward alternative peptides. This holds significance because HIMS has capital investments linked to its GLP-1 operations following previous FDA compounding limitations.
The investment firm exercised caution in its perspective. It characterized this development as “an initial small step” and indicated no anticipated near-term earnings estimate modifications unless the FDA proceeds with official determinations.
The regulatory agency additionally noted that the majority of substances under consideration continue to present potential safety concerns under existing guidance.
Additional HIMS Developments
HIMS has recently incorporated Novo Nordisk’s FDA-cleared GLP-1 therapies into its service offerings, including Wegovy in both injectable and oral formulations. The Wegovy tablet represents the sole FDA-authorized GLP-1 weight management pill on the market.
The platform will additionally provide Ozempic injection devices, though these carry approval exclusively for Type 2 diabetes treatment.
Rivalry within the GLP-1 sector has intensified. Amazon Pharmacy launched same-day delivery service for Eli Lilly’s recently approved GLP-1 medication Foundayo, creating competitive pressure for both Novo Nordisk and HIMS.
Regarding insider transactions, CFO Oluyemi Okupe submitted documentation to divest stock valued at roughly $4.9 million. Throughout the past three-month period, company insiders have collectively sold approximately $3.4 million, with zero acquisition activity documented.
HIMS currently trades at a price-to-earnings multiple in the 45-47x range. InvestingPro’s evaluation indicates the stock appears overvalued compared to its Fair Value calculation. The organization maintains a market capitalization of approximately $5.54 billion and serves over 2 million subscribers.
BofA’s EBITDA projection for 2026 remains roughly 21% beneath Wall Street consensus, a discrepancy the firm has highlighted in earlier research communications.
